SCHEMBL3267325

SCHEMBL3267325

COc1ccccc1CNc1cc(-c2ccccc2C)c2cc(NCc3cccnc3)ccc2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 16/20 0.49
CYP2C19 P33261 16/20 0.49
CYP1A2 P05177 15/20 0.49
CYP2D6 P10635 15/20 0.49
HSD17B10 Q99714 13/20 0.49
ALDH1A1 P00352 9/20 0.49
TSHR P16473 9/20 0.49
ALOX15 P16050 7/20 0.49
USP2 O75604 5/20 0.49
CLK4 Q9HAZ1 7/20 0.48
KDM4E B2RXH2 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 2/20 0.46
GLA P06280 1/20 0.46
MAPK1 P28482 4/20 0.46
CYP2C9 P11712 3/20 0.46
HPGD P15428 2/20 0.46
ALOX12 P18054 1/20 0.46
LMNA P02545 4/20 0.46
MEN1 O00255 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3268428 0.90 CYP1A2 (0.51) CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10
SCHEMBL3268678 0.90 CYP1A2 (0.52) CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10
SCHEMBL3267094 0.87 CYP1A2 (0.47) CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10
SCHEMBL3268137 0.86 CYP1A2 (0.47) CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10
SCHEMBL8509984 0.83 KCNH2 (0.49) CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10
SCHEMBL3268321 0.82 CYP1A2 (0.53) CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10
SCHEMBL3267284 0.79 EGFR (0.48) CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10
SCHEMBL3268743 0.78 NTRK1 (0.48) CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10
SCHEMBL3268584 0.77 CYP1A2 (0.52) CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10
SCHEMBL3267190 0.77 DHFR (0.50) ALDH1A1KDM4ESMN1; SMN2HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399674-B2 Quinolines HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US claimed
US-20120136018-A1 QUINOLINES KOLCZEWSKI SABINE (DE) 2012-05-31 US claimed
EP-2195296-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-06-16 EP claimed
US-20090088451-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 US claimed
WO-2009040290-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO claimed
US-8399674-B2 Quinolines HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-20120136018-A1 QUINOLINES KOLCZEWSKI SABINE (DE) 2012-05-31 US disclosed
EP-2195296-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-06-16 EP disclosed
US-20090088451-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 US disclosed
WO-2009040290-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088451-A1 QUINOLINES HTR5A, HTR1A, HTR1E CYP3A4 329/4885CYP2C19 288/4885CYP1A2 161/4885
US-20120136018-A1 QUINOLINES HTR5A, HTR1A, HTR1E CYP3A4 329/4885CYP2C19 288/4885CYP1A2 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.